Plummeting 6.8%, way outperforming the market, Immune Design Corp. (NASDAQ:$IMDZ)’s shares are suffering a serious outlook.

Let’s take a look back on Immune Design’s last earnings report.

Narrower-than-expected Loss in Q2

The company incurred 2Q17 Loss of 54 cents per share, narrower than the Zacks Consensus Estimate of 65 cents.

2Q17

• The company’s total revenue was $0.7 million, down from $1.1 million in the year ago quarter
• Research and development expenses were down 4.6% to $10.9 million
• General and administrative expenses decreased by 1.5% to $3.9 million

Pipeline

Immune Design is developing multiple new products using its two discovery platforms, ZVex and GLAAS, in the field of immuno-oncology.

Of the two products, CMB305 is currently in trials, although data has not been optimal. The other, G100, is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study. In this trial, over a third of patients have achieved a partial response, and 50% of evaluable patients experience shrinkage of untreated distal lesions.

New Estimates

In the past month, investors have seen a downward trend in fresh estimates. At this time, Immune sees a new Growth Score of B. The stock sees a grade of F on the value side, situating it in the fifth quintile for investment strategy. Hence, the company’s stock is suitable for growth and momentum investors.

Featured Image: twitter